TY - JOUR
T1 - Levemopamil injection after cerebral oligemia reduces spatial memory deficits in rats
AU - Heim, Christine
AU - Sieklucka, Maria
AU - Sontag, Karl Heinz
N1 - Funding Information:
The skillful technical assistance of H. Ropte and M. Schindier is gratefully acknowledged. Levemopamil was kindly provided by Knoll AG, Germany. The authors are indebted to Dr. H. Stadler (Biometra, G6ttingen, Germany) for the use of his technical equipment for ACh measurement. We thank Dr. N. N. Osborne for his helpful comments while preparing the manuscript and Dr. R. Morris for his valuable criticism. This study was supported by Deutsche Forschungs-gemeinschaft, and BMFT 01KL9101/0 Sonderforschungsbereich 330 "Or-ganprotektion."
PY - 1994/7
Y1 - 1994/7
N2 - Transient reduction of cerebral blood flow to oligemic levels as produced by bilateral clamping of carotid arteries (BCCA) in pentobarbital anesthetized Wistar rats leads to spatial orientation deficiencies in a water maze test 8-10 days after surgery. These deficiencies are more pronounced in 4-month-old than in 6-week-old animals. Levemopamil [(2S)-2-isopropyl-5-(methylphenethylamino)-2-phenylvaleronitrile hydrochloride], a Ca2+ channel blocker and 5-HT2 antagonist, prevents the deficiencies in groups of animals of both ages, even when administered 24 h after the transient vessel occlusion. Levemopamil did not influence the maze performance of sham-operated control rats. Levemopamil, therefore, appears to modulate mechanisms that are altered specifically either by, or as a consequence of, the BCCA procedure. Levemopamil did not influence the altered GABA or ACh content in different vulnerable brain structures following BCCA, showing that the substance acts via additional mechanisms affected by the BCCA procedure.
AB - Transient reduction of cerebral blood flow to oligemic levels as produced by bilateral clamping of carotid arteries (BCCA) in pentobarbital anesthetized Wistar rats leads to spatial orientation deficiencies in a water maze test 8-10 days after surgery. These deficiencies are more pronounced in 4-month-old than in 6-week-old animals. Levemopamil [(2S)-2-isopropyl-5-(methylphenethylamino)-2-phenylvaleronitrile hydrochloride], a Ca2+ channel blocker and 5-HT2 antagonist, prevents the deficiencies in groups of animals of both ages, even when administered 24 h after the transient vessel occlusion. Levemopamil did not influence the maze performance of sham-operated control rats. Levemopamil, therefore, appears to modulate mechanisms that are altered specifically either by, or as a consequence of, the BCCA procedure. Levemopamil did not influence the altered GABA or ACh content in different vulnerable brain structures following BCCA, showing that the substance acts via additional mechanisms affected by the BCCA procedure.
UR - http://www.scopus.com/inward/record.url?scp=0028241502&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028241502&partnerID=8YFLogxK
U2 - 10.1016/0091-3057(94)90322-0
DO - 10.1016/0091-3057(94)90322-0
M3 - Article
C2 - 7938114
AN - SCOPUS:0028241502
VL - 48
SP - 613
EP - 619
JO - Pharmacology Biochemistry and Behavior
JF - Pharmacology Biochemistry and Behavior
SN - 0091-3057
IS - 3
ER -